Team reports promising results of phase 1/2 trial of rociletinib in EGFR lung cancer
The New England Journal of Medicine reports results of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib (CO-1686) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had ...
Apr 29, 2015
0
7